rovazolac   Click here for help

GtoPdb Ligand ID: 9625

Synonyms: A-110 | ALX-101 | example 36 [WO2013130892]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: This compound is claimed as example 36 in patent WO2013130892 [1], as a liver X receptor (LXR) modulator, with potential clinical utility as a topical agent for the treatment of inflammatory skin conditions. To elucidate the origins of this agent we used the IUPAC name submitted to the WHO for the INN rovazolac, which resolved to the SMILES string used to generate the chemical structure shown here. This SMILES string via SureChEMBL, identified patents claiming the structure which tracked forward to Relaxar Therapeutics disclosed development pipeline, and the research code ALX-101. However, this association is our prediction as the structure has not been formally disclosed in peer reviewed literature.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 0
Rotatable bonds 8
Topological polar surface area 86.64
Molecular weight 452.1
XLogP 5.02
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCOC(=O)Cn1nc(cc1c1ccc(cc1)c1cccc(c1)S(=O)(=O)C)C(F)(F)F
Isomeric SMILES CCOC(=O)Cn1nc(cc1c1ccc(cc1)c1cccc(c1)S(=O)(=O)C)C(F)(F)F
InChI InChI=1S/C21H19F3N2O4S/c1-3-30-20(27)13-26-18(12-19(25-26)21(22,23)24)15-9-7-14(8-10-15)16-5-4-6-17(11-16)31(2,28)29/h4-12H,3,13H2,1-2H3
InChI Key ZUMNJDGBYXHASJ-UHFFFAOYSA-N
Immunopharmacology Comments
Activation of LXR is associated with inflammation, hyperproliferative and/or disordered skin barrier differentiation. Targeting LXR in inflammation is reviewed in [3].
Immunopharmacology Disease
Disease X-Refs Comment References
Atopic dermatitis Disease Ontology: DOID:3310
OMIM: 603165
Phase 2 clinical candidate for atopic dermatitis.